person · Reporting owner
Farajallah Awny Samaan Botros
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Chief Medical Officer | August 10, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TAKEDA PHARMACEUTICAL CO LTD
Report date August 10, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 116,177 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 14,006 · Balance 116,177 F1: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 13, 2026 01:54 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 14,006 | $17.10 | $239,502.60 |
DisclosureSEC source: 0001493152-26-037515 · ownership.xml · nonDerivative · entry 1 Farajallah Awny Samaan Botros · CIK 0002121389 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,177 F1 · kind: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:06 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 17,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000254 · wk-form4_1783375562.xml · nonDerivative · entry 1 Farajallah Awny Samaan Botros · CIK 0002121389 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,183 F1 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.